A Randomized, Double Blind, Placebo Controlled Phase II Trial to Evaluate the Safety and Efficacy of recMAGE-A3 + AS15 ASCI in Patients With MAGE-A3 Positive Muscle Invasive Bladder Cancer After Cystectomy
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Zastumotide (Primary) ; AS15
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms MAGNOLIA
- 15 Jun 2017 Status changed from active, no longer recruiting to discontinued.
- 26 Apr 2017 This trial has been completed in Netherland as per European Clinical Trials Database record.
- 20 Mar 2017 This trial has been completed in Germany.